At the news
? BULLISHIMPACT 6/10 6-K filed Jul 14, 2026 at 07:54 ET
Mesoblast announced it has enrolled the target of 300 patients in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. Top-line results are expected in mid-CY2027. The trial has RMAT designation from the FDA, and the company is proceeding with commercial manufacturing in parallel. This milestone de-risks the program but does not provide efficacy data.
- At least 300 patients treated in the placebo-controlled pivotal Phase 3 trial of rexlemestrocel-L for CLBP.
- Top-line results expected in mid-CY2027 after the last patient completes 12-month follow-up.
- Rexlemestrocel-L has FDA RMAT designation, providing eligibility for priority review upon BLA filing.
- Management estimates potential peak year revenue of >$10 billion with single-digit market penetration (forward-looking statement).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access